NCT01534078 Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma Status COMPLETED Phase PHASE2
NCT01523847 A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL) Status COMPLETED Phase PHASE2
NCT01468311 Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma Status TERMINATED Phase PHASE1/PHASE2
NCT01453504 Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma Status COMPLETED Phase PHASE1/PHASE2
NCT01452334 Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy Status WITHDRAWN Phase PHASE1
NCT01447056 Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases Status COMPLETED Phase PHASE1
NCT01393106 Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma Status COMPLETED Phase PHASE2
NCT01351545 A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Status RECRUITING Phase N/A
NCT01333605 IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma Status UNKNOWN Phase PHASE2
NCT01333046 Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT01271127 Screening for Coronary Artery Disease After Mediastinal Irradiation Status COMPLETED Phase NA
NCT01263899 A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies Status COMPLETED Phase PHASE2
NCT01251107 Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma Status COMPLETED Phase PHASE3
NCT01231269 Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma Status ACTIVE_NOT_RECRUITING Phase NA
NCT01228461 Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients Status COMPLETED Phase N/A
NCT01220297 Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT Status TERMINATED Phase PHASE2
NCT01217229 Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma Status COMPLETED Phase PHASE2